CNMDCONMED Corporation
Is the price fair?
Undemanding: cheap against its own history and cheap vs its sector.
Cheap vs its own history: P/E 26.6 vs a 49.1 median over 33 quarters (−46% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CNMD's price assumes
CONMED Corporation trades at 26.6× earnings against 28.1× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 28.1 · cheaper than the typical name in its group
- Price / sales
- 1.07
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 1.41
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 1.65
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.41
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 20.6
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.65
- Healthcare median P/E503 names
- 27.9
- Medical Devices median P/E64 names
- 28.1
- Market capitalisation30.0 million shares, counted Jul 27, 2026
- $1.47B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $43.71 |
| Its own P/E history, median | $90.81 |
| Its own P/E history, upper quartile | $134.33 |
| 52-week range | $32.11 – $51.88 |
| Today | $49.14 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.